Is there any evidence supporting the use of GLP-1 type drugs in children and adolescents?

Read full text Summarise with VIRAT
Authors: Tripdatabase
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

GLP-1 receptor agonists show promise in treating obesity and type 2 diabetes in adolescents 12 years and older, with modest efficacy and manageable safety profiles, though data for younger children and long-term effects are limited.

Fields of Study & Subjects

Pharmacology and Obesity Treatment Diabetes Treatment and Management Obesity Physical Activity Diet

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
30 March 2026
Language
EN